Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

Hedwig M. Blommestein, Nigel Armstrong, Steve Ryder, Sohan Deshpande, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen, Johan L. Severens, Maiwenn J. Al

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalPharmacoeconomics
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2016

Keywords

  • LENALIDOMIDE
  • Best Suoortive Care
  • Evidence Review Group
  • Acute Myeloid Leukemia
  • Appraisal Committee

Cite this